Clinical data from a 16-patient pediatric study demonstrate the safety and efficacy of Asceniv in younger populations, ...

AASM recommends against use of combination of CBT-I plus medication over CBT-I alone for chronic insomnia disorder.

Nereus ™ (tradipitant) is now available for the prevention of vomiting induced by motion in adults. According to manufacturer Vanda Pharmaceuticals, the product is available by ...

Patients treated with dilanubicel demonstrated faster hematopoietic recovery and had a markedly lower incidence of severe acute GVHD. HealthDay News — Adding dilanubicel, a cryopreserved, cord blood ...

The approval is supported by bioequivalence data assessing the once-daily extended-release formulation to twice-daily immediate-release ruxolitinib in healthy participants.

Despite earlier antibiotic exposure being more common in those with celiac disease, researcher says 'the connections are much more complex' ...

Radiomics-based early detection model surpasses radiologists for detecting PDA at visually occult prediagnostic stage.

The newly approved oral formulation features a smaller pill size in 1.5mg, 4mg, and 9mg strengths while maintaining the efficacy and safety profile of the previous oral semaglutide version.

Under the Bridge program, eligible beneficiaries can get Medicare coverage of GLP-1s for obesity for a $50 copay. Extending the short-term GLP-1 Bridge program is good news for eligible Medicare ...

Data from ARTISTRY trials demonstrated that switching to a single-tablet regimen of bictegravir and lenacapavir is noninferior to continuing current antiretroviral therapy.

Reasonable first-line therapies include dietary and lifestyle modifications such as increasing fiber intake. HealthDay News — Dietary and lifestyle modifications are reasonable first-line therapies ...